** Johnson & Johnson JNJ.N, fresh off a $14.6 bln deal to buy neurological drugmaker Intra-Cellular ITCI.O, reported fourth-quarter revenues and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments
** Median PT of 24 brokerages covering the stock is $169.5- LSEG data
SALES OUTLOOK LOOKS ACHIEVABLE
** J.P.Morgan ("neutral," PT: $185) sees JNJ's innovative medicines segment poised for growth, and ITCI acquisition will enhance its business
**Despite challenges in China and a pause in the Varipulse used to treat irregular heartbeats launch in the U.S., JPM expects the MedTech segment to grow steadily over time as it shifts towards higher-growth areas
** TD Cowen ("buy," PT: $185) sees JNJ's sales guidance achievable and expects numerous planned product launches to support growth in the latter half of the year
** Leerink Partners ("outperform," PT: $169) expects low double-digit global sales in 2025; says price drop in Tremfya, used to treat certain inflammatory conditions, in late 2024 was due to a mix of factors
** Morningstar (fair value: $164) expects JNJ's growth to slow in 2025 due to competition from biosimilars for Stelara, used to treat inflammatory bowel disease $(IBD)$
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.